Glutamate release inhibition ineffective in levodopa-induced motor complications

Bara-Jimenez W., Dimitrova T. D. , Sherzai A., Aksu M. , Chase T. N.

MOVEMENT DISORDERS, cilt.21, sa.9, ss.1380-1383, 2006 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Konu: 9
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1002/mds.20976
  • Sayfa Sayıları: ss.1380-1383


Reported benefits of various glutamatergic receptor antagonists in Parkinson's disease (PD) prompted an evaluation of the antidyskinetic effect of a putative glutamate release inhibitor in 15 moderately advanced patients. In a 3-week, double-blind, proof-of-concept study, riluzole (200 mg/day) failed to alter parkinsonian or levodopa-induced motor complication severity. Opposing effects of a generalized inhibition of glutamate-mediated synaptic transmission may limit the usefulness of this approach to treat PD. (c) 2006 Movement Disorder Society.